Targeting the M1 muscarinic receptor in neurodegenerative disease: the role of receptor phosphorylation
By Sophie Bradley | Aug 25, 2022
Sophie Bradley, an associate director in our Pre-Clinical Translational Neuroscience department, presented at the FASEB G Protein-coupled Receptor Kinases and Arrestins Conference: Key Modulators of Signal Transduction. The presentation focussed on the M1 receptor as a potential therapeutic target in neurodegenerative disease and highlighted research conducted at both Sosei Heptares and the University of Glasgow.
The presentation discussed HTL9936, a selective M1 receptor agonist designed by Sosei Heptares using their structure-based drug design (SBDD) platform. Selective approaches to activate the M1 receptor have the potential to improve cognitive function in Alzheimer’s Disease patients while minimizing side-effects associated with previous attempts to target this receptor. The ground-breaking research on HTL9936, from structure through to clinical studies, was recently published in Cell.
Federation of American Societies for Experimental Biology (FASEB): The G Protein-coupled Receptor Kinases and Arrestins Conference: Key Modulators of Signal Transduction
21–26 August 2022
Jupiter, Florida USA